Crinetics Pharmaceuticals Q3 2024 Earnings Report

Crinetics Pharmaceuticals EPS Results

• Actual EPS: -$0.96
• Consensus EPS: -$0.91
• Beat/Miss: Missed by -$0.05
• One Year Ago EPS: -$1.01

Crinetics Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $0.22 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Crinetics Pharmaceuticals Announcement Details

• Quarter: Q3 2024
• Date: 11/12/2024
• Time: After Market Closes

Crinetics Pharmaceuticals (NASDAQ:CRNX), a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.